These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3681368)

  • 41. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%.
    Rallis E; Economidi A; Verros C; Papadakis P
    J Drugs Dermatol; 2006 Oct; 5(9):906-7. PubMed ID: 17039660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topical chemotherapy of mycosis fungoides.
    Grekin DA; Zackheim HS; Epstein EH
    Cutis; 1979 Nov; 24(5):543-6. PubMed ID: 520032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term control of mycosis fungoides of the hands with topical bexarotene.
    Lain T; Talpur R; Duvic M
    Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ointment-based mechlorethamine treatment for mycosis fungoides.
    Price NM; Hoppe RT; Deneau DG
    Cancer; 1983 Dec; 52(12):2214-9. PubMed ID: 6640491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma.
    Van Scott EJ; Grekin DA; Kalmanson JD; Vonderheid EC; Barry WE
    Cancer; 1975 Nov; 36(5):1613-8. PubMed ID: 1192353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy.
    Vonderheid EC; Van Scott EJ; Wallner PE; Johnson WC
    Cancer Treat Rep; 1979 Apr; 63(4):681-9. PubMed ID: 109206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mycosis fungoides, nitrogen mustard and skin cancer.
    Du Vivier A; Vonderheid EC; Van Scott EJ; Urbach F
    Br J Dermatol; 1978 Jul; 99(1):61-3. PubMed ID: 678466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topical mechlorethamine therapy for early stage mycosis fungoides.
    Ramsay DL; Halperin PS; Zeleniuch-Jacquotte A
    J Am Acad Dermatol; 1988 Oct; 19(4):684-91. PubMed ID: 3183094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term topical nitrogen mustard treatment does not induce pulmonary fibrosis in MF patients.
    Nielsen M; Rasmussen K; Knudsen N; Thestrup-Pedersen K
    Acta Derm Venereol; 1994 Jan; 74(1):70-1. PubMed ID: 7908491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Photochemotherapy and topical nitrogen mustard in the treatment of mycosis fungoides.
    du Vivier A; Vollum DI
    Br J Dermatol; 1980 Mar; 102(3):319-22. PubMed ID: 7370179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aspects of the treatment of mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Study Group.
    Molin L; Thomsen K; Volden G; Groth O; Fischer T; Nordentoft A; Zachariae H
    Cutis; 1980 Feb; 25(2):155-7, 160-1. PubMed ID: 6153595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Response to topical corticosteroid monotherapy in mycosis fungoides.
    Kartan S; Shalabi D; O'Donnell M; Alpdogan SO; Sahu J; Shi W; Porcu P; Cha J; Nikbakht N
    J Am Acad Dermatol; 2021 Mar; 84(3):615-623. PubMed ID: 32428610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy.
    Chiam LY; Chan YC
    Br J Dermatol; 2007 Mar; 156(3):560-2. PubMed ID: 17300249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome.
    Patrawala SA; Broussard KC; Wang L; Zic JA
    Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skin directed therapy for mycosis fungoides: a review.
    Berthelot C; Rivera A; Duvic M
    J Drugs Dermatol; 2008 Jul; 7(7):655-66. PubMed ID: 18664158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group.
    Hurabielle C; Ingen-Housz-Oro S; Ortonne N; Cornillet-Lefèbvre P; Merah A; D'Incan M; Joly P; Franck N; Estève E; Maubec E; Grange F; Machet L; Laroche L; Barete S; Dalac S; Mortier L; Michel C; Quereux G; Saiag P; Ram-Wolff C; Lenormand B; Wechsler J; Bastuji-Garin S; Bagot M; Delfau-Larue MH
    Br J Dermatol; 2015 Oct; 173(4):1015-23. PubMed ID: 26149621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topical nitrogen mustard induced carcinogenesis.
    Kravitz PH; McDonald CJ
    Acta Derm Venereol; 1978; 58(5):421-5. PubMed ID: 82352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Modern therapy of mycosis fungoides].
    Roenigk HH
    Hautarzt; 1983 Jun; 34(6):266-72. PubMed ID: 6874333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The treatment of mycosis fungoides with ointment-based mechlorethamine.
    Price NM; Deneau DG; Hoppe RT
    Arch Dermatol; 1982 Apr; 118(4):234-7. PubMed ID: 7065680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration.
    Price NM
    Arch Dermatol; 1977 Oct; 113(10):1387-9. PubMed ID: 911166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.